Clinical development of the GnRH agonist leuprolide acetate depot

Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive trea...

Descripción completa

Detalles Bibliográficos
Autor principal: Chwalisz, Kristof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Special Issue
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201295/
https://www.ncbi.nlm.nih.gov/pubmed/37223757
http://dx.doi.org/10.1016/j.xfre.2022.11.011
Descripción
Sumario:Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection.

Ejemplares similares